Core Scientific is caught between a sell-side consensus that still sees the stock roughly doubling from here and a short position that won't budge — and the price keeps falling.
The data published earlier today captured most of this story, but one development is worth pulling forward. Analysts lifted targets aggressively after the July 28 earnings print, even as the stock dropped 12.6% on the day. B. Riley raised its target to $42 from $33, Macquarie moved to $38, Canaccord to $36, and Needham to $35 — all maintaining positive ratings. KBW went further and upgraded to Outperform. The consensus mean sits around $37, against a stock trading at $16.51. That gap is not a data error; it reflects a Street that believes the AI and HPC colocation thesis is intact while the market has priced in execution risk from customer concentration and the pace of the CoreWeave contract ramp. The bull case rests on power deployment timing and the colocation pipeline. The bear case is simpler: one contract, one client, and every delay costs more than the model allows.
Short positioning tells a story of stale conviction rather than fresh aggression. At 20.2% of the free float, short interest has barely moved all week — down less than 2% over seven days and off roughly 10% from the month prior. Bears added during the July squeeze, trimmed marginally, and have since stopped moving. The ORTEX short score sits at 67.5, down from 69.1 two weeks ago, reflecting a slight softening in the positioning signal but still elevated in absolute terms. Crucially, the lending market is not tight: availability runs at around 212% — meaning roughly two shares are available to borrow for every one already out on loan — and cost to borrow is just 0.58%, despite rising about 35% over the past week. That week-on-week rise in CTB is worth noting, but from such a low base it signals a minor uptick in borrow demand rather than any squeeze dynamic.
Options traders are leaning slightly the other way. The put/call ratio has drifted to 0.45, about 1.4 standard deviations below its 20-day average of 0.47. That puts it toward the call-heavy end of its recent range — not an aggressive bull signal, but a hint that options positioning is not as defensive as the price action might suggest. The year's most defensive PCR reading was 0.63; the current reading is nowhere near that. The setup is muted rather than polarised.
The institutional picture adds one notable detail. Situational Awareness LP cut its position by nearly 12 million shares in the most recent filing, while Jericho Capital added roughly 11 million and Valiant Capital added 10 million. BlackRock added a further 3.5 million. The headline is that active managers are actively redistributing — aggressive buyers and one significant seller, with passive flows staying roughly flat. Director-level insiders have picked up small amounts this month, while the CLO has been a consistent seller throughout August. Neither side of that trade is large enough to move the needle, but the director purchases are at least occurring into weakness.
The next scheduled earnings event is November 2. Between now and then, the stock's trajectory depends largely on whether the sector-wide pressure — IREN fell 15% on the week, RIOT and CLSK each dropped around 4% — stabilises, and whether any update on billable power deployment under the CoreWeave contract arrives ahead of the print. Short interest has shown no sign of covering into the slide; whether that changes as the stock approaches technically significant levels is the key dynamic to watch.
See the live data behind this article on ORTEX.
Open CORZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
